/s/ Joseph B. Armes, /s/ Joseph B. Armes ; Name:, Joseph B. Armes ; Title:, Chairman of the Board,
Item 7.01 Regulation FD Disclosure · AAR CORP.’s Vice President, Chief Financial Officer and Treasurer, Michael J. Sharp, presented at the Cowen and Company 37th Annual Aerospace/Defense & Transportation Conference on Thursday, February 4, 2016 in New York City. Attached as Exhibit 99.1 are the slides used by Mr. Sharp in his presentation. The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of t...
Item 1.01 Entry into a Material Definitive Agreement · On September 21, 2016, Hyperdynamics Corporation (“Hyperdynamics,” the “Company,” “we” or “us”), through its wholly-owned subsidiary, SCS Corporation (“SCS”) received an implementing Presidential Decree from the Republic of Guinea authorizing a Second Amendment (the “Second Amendment”) to the Hydrocarbon Production Sharing Contract, dated September 22, 2006, between SCS and the Republic of Guinea, as amended on Marc...
1., A copy of the Financial Institution Bond Standard Form No. 14, Bond No. FIB 0000609-11 in the amount of $900,000 (the “Fidelity Bond”); ; 2., A copy of the Secretary’s Certificate certifying the resolutions adopted by the Board of Directors, including all of the directors who are not interested persons, on July 21, 2008, approving the amount, type, form and coverage of the Fidelity Bond and including a statement as to the amount of the single insured bond that would have been obtained if the joint insured bond was not obtained and the period for which premiums for the Fidelity Bond have been paid; and ; 3., A copy of the agreement between the named insureds pursuant to Rule 17g-1(f).
0001104659-20-088330.txt : 20200730 0001104659-20-088330.hdr.sgml : 20200730 20200730180518 ACCESSION NUMBER: 0001104659-20-088330 CONFORMED SUBMISSION TYPE: FWP PUBLIC DOCUMENT COUNT: 24...
Exhibit Number, Exhibit Title or Description ; 23.1, Consent of Ernst & Young LLP, Avast plc’s independent auditors. ; 99.1, Management’s Discussion and Analysis of Financial Condition and Results of Operations of Avast. ; 99.2, Investor presentation, dated September 7, 2022. ; 99.3, Risks Related to the Avast plc Business. ; 99.4, Unaudited pro forma condensed combined financial information of NortonLifeLock Inc. giving effect to the acquisition of Avast plc, which includes the unaudited pro forma condensed combined statement of financial position as of July 1, 2022 and the unaudited pro forma condensed combined statement of comprehensive income for the year ended April 1, 2022 and the three months ended July 1, 2022, and the notes related thereto. ; 99.5, The historical audited consolidated financial statements and financial statement schedule of Avast plc as of and for each of the years ended December 31, 2021 and 2020, the notes related thereto and the related reports of Ernst & Young LLP, Avast plc’s independent auditors. ; 99.6, The historical unaudited condensed consolidated financial statements and financial statement schedule of Avast plc as of and for each of the six months ended June 30, 2022 and 2021, and the notes related thereto. ; 104, The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · WASHINGTON, D.C. 20549 · FORM 8-K · CURRENT REPORT · PURSUANT TO SECTION 13 OR 15(D) OF THE · SECURITIES EXCHANGE ACT OF 1934 · Date of Report (date of earliest event reported): June 9, 2021 · (Exact name of registrant as specified in its charter)
Proxy Statement for Annual Meeting of Shareholders, 1 ; Frequently Asked Questions About the Annual Meeting, 1 ; Election of Directors (Proposal No. 1), 4 ; Information Regarding Nominees, 4 ; Director Skills & Demographics, 5 ; Emeritus Directors of the Board of Directors, 11 ; Ratification of the Appointment of KPMG LLP (Proposal No. 2), 11 ; Audit and Non-Audit Fees, 12 ; Advisory Vote on the Compensation of our Named Executive Officers (Proposal No. 3), 12 ; Security Ownership of Certain Beneficial Owners and Management, 13 ; Corporate Governance, 15 ; Meetings of the Board of Directors and its Committees, 15 ; Board Leadership Structure, 19 ; The Board’s Annual Self-Evaluation, 19 ; The Board’s Role in Risk Oversight, 20 ; Communications to the Board, 21 ; Code of Ethics and Environmental, Social & Governance, 21 ; Prohibition on Hedging or Pledging of Company Stock, 22 ; Director Independence, 22 ; Director Compensation, 22 ; Policy on Poison Pills, 24 ; Compensation Committee Interlocks and Insider Participation, 24 ; Management Information, 24 ; Compensation Discussion and Analysis, 26 ; Overview, 26 ; Business Strategy and Summary of 2023 Financial and Business Performance, 26 ; 2023 Executive Compensation Actions, 27 ; Say-on-Pay Vote, 28 ; Primary Responsibilities of our Compensation Committee, 28 ; Compensation Philosophy and Primary Objectives, 29 ; Compensation Process, 30 ; Elements of Compensation, 33 ; Compensation Actions in 2023 and 2024, 36 ; Clawback Policy, 38 ; Stock Ownership Guidelines, 39 ; Termination-Based Compensation, 39 ; Limitations on Tax Deductibility of Executive Compensation, 40 ; Perquisites and Other Benefits, 40
SECURITIES AND EXCHANGE COMMISSION · Washington, D.C. 20549 · FORM 8-K · CURRENT REPORT · PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 · Date of Report (Date of Earliest Event Reported) – January 11, 2006 · WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter)
0000950157-24-000203.txt : 20240213 0000950157-24-000203.hdr.sgml : 20240213 20240213172458 ACCESSION NUMBER: 0000950157-24-000203 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT...